{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:44:08Z","timestamp":1792856648728,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T00:00:00Z","timestamp":1763251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T00:00:00Z","timestamp":1763251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK136679"],"award-info":[{"award-number":["R01DK136679"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R56DK104753"],"award-info":[{"award-number":["R56DK104753"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["UE5DK137308"],"award-info":[{"award-number":["UE5DK137308"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U54DK083912"],"award-info":[{"award-number":["U54DK083912"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U24DK100845"],"award-info":[{"award-number":["U24DK100845"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U01DK116101"],"award-info":[{"award-number":["U01DK116101"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K01DK127002"],"award-info":[{"award-number":["K01DK127002"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019337","name":"Miami Clinical and Translational Science Institute, University of Miami","doi-asserted-by":"publisher","award":["UM1TR004556"],"award-info":[{"award-number":["UM1TR004556"]}],"id":[{"id":"10.13039\/100019337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Alport syndrome (AS) is a hereditary glomerulopathy caused by mutations in the\n                    <jats:italic>COL4A3<\/jats:italic>\n                    ,\n                    <jats:italic>COL4A4<\/jats:italic>\n                    , or\n                    <jats:italic>COL4A5<\/jats:italic>\n                    genes, leading to progressive kidney decline and extrarenal manifestations. Advances in genetic testing have enabled the reclassification of AS into X-linked, autosomal recessive, and autosomal dominant forms, facilitating more accurate diagnosis and risk stratification. While renin-angiotensin-aldosterone system (RAAS) blockade remains the foundation of treatment to delay kidney failure, it does not directly target the underlying molecular pathology. Adjunctive commercially available metabolic modulators, including SGLT2i, mineralocorticoid receptor antagonists, ezetimibe and GLP-1 receptor agonists, may offer additional kidney protection. Ameliorating therapies being tested in Phase II trials include endothelin receptor antagonists (e.g., atrasentan), dual endothelin receptor antagonist and angiotensin II receptor inhibition (e.g., sparsentan) FXR agonists (e.g., vonafexor), inducers of cholesterol efflux (e.g., VAR200 and R3R01), and NOX1\/4 inhibitors (e.g., setanaxib), several of which are currently being evaluated in clinical trials. Novel strategies such as exon skipping, gene editing, and nonsense mutation readthrough (e.g., ELX-02) are advancing toward precision medicine approaches as disease modifying agents targeting the genetic cause of AS. Moreover, therapies targeting mitochondrial function, such as mitophagy enhancers, have demonstrated preclinical promise. Stem cell-based approaches are also being explored for their regenerative and anti-fibrotic effects. This review summarizes the current landscape of AS classification and treatment, highlighting both standard interventions and experimental therapies. Emphasis is placed on the molecular mechanisms underlying podocyte injury and fibrosis, recent preclinical findings, and ongoing clinical trials that may shift future therapeutic paradigms.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s00467-025-07046-z","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T22:38:57Z","timestamp":1763332737000},"page":"607-619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["From RAAS blockade to regenerative medicine: evolving treatment strategies in Alport syndrome"],"prefix":"10.1007","volume":"41","author":[{"given":"Claudia","family":"Lo Re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Fornoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,16]]},"reference":[{"key":"7046_CR1","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1056\/NEJMra022296","volume":"348","author":"BG Hudson","year":"2003","unstructured":"Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG (2003) Alport\u2019s syndrome, Goodpasture\u2019s syndrome, and type IV collagen. N Engl J Med 348:2543\u20132556","journal-title":"N Engl J Med"},{"key":"7046_CR2","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1126\/science.2349482","volume":"248","author":"DF Barker","year":"1990","unstructured":"Barker DF, Hostikka SL, Zhou J, Chow LT, Oliphant AR, Gerken SC et al (1990) Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 248:1224\u20131227","journal-title":"Science"},{"key":"7046_CR3","first-page":"563","volume":"37","author":"MD Crawfurd","year":"1968","unstructured":"Crawfurd MD, Toghill PJ (1968) Alport\u2019s syndrome of hereditary nephritis and deafness. Q J Med 37:563\u2013576","journal-title":"Q J Med"},{"key":"7046_CR4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1081\/JDI-100101961","volume":"22","author":"JP Gr\u00fcnfeld","year":"2000","unstructured":"Gr\u00fcnfeld JP (2000) Contemporary diagnostic approach in Alport\u2019s syndrome. Ren Fail 22:759\u2013763","journal-title":"Ren Fail"},{"key":"7046_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1053\/j.akdh.2024.02.004","volume":"31","author":"E Chavez","year":"2024","unstructured":"Chavez E, Goncalves S, Rheault MN, Fornoni A (2024) Alport syndrome. Advances in Kidney Disease and Health 31:170\u2013179","journal-title":"Advances in Kidney Disease and Health"},{"key":"7046_CR6","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1681\/ASN.2009070784","volume":"21","author":"MR Bekheirnia","year":"2010","unstructured":"Bekheirnia MR, Reed B, Gregory MC, McFann K, Shamshirsaz AA, Masoumi A et al (2010) Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol 21:876\u2013883","journal-title":"J Am Soc Nephrol"},{"key":"7046_CR7","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1681\/ASN.2020071065","volume":"32","author":"J Gibson","year":"2021","unstructured":"Gibson J, Fieldhouse R, Chan MMY, Sadeghi-Alavijeh O, Burnett L, Izzi V et al (2021) Prevalence estimates of predicted pathogenic COL4A3-COL4A5 variants in a population sequencing database and their implications for Alport syndrome. J Am Soc Nephrol 32:2273\u20132290","journal-title":"J Am Soc Nephrol"},{"key":"7046_CR8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/cge.12258","volume":"86","author":"C Fallerini","year":"2014","unstructured":"Fallerini C, Dosa L, Tita R, Del Prete D, Feriozzi S, Gai G et al (2014) Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases. Clin Genet 86:252\u2013257","journal-title":"Clin Genet"},{"key":"7046_CR9","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1681\/ASN.0000000580","volume":"36","author":"M Zellers","year":"2025","unstructured":"Zellers M, Solanki K, Kelly MA, Murphy KM, Retterer K, Kirchner HL et al (2025) Genotype-first analysis in an unselected health system-based population and phenotypic severity of COL4A5 variants. J Am Soc Nephrol 36:1138\u20131151","journal-title":"J Am Soc Nephrol"},{"key":"7046_CR10","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.xkme.2020.05.014","volume":"2","author":"BA Warady","year":"2020","unstructured":"Warady BA, Agarwal R, Bangalore S, Chapman A, Levin A, Stenvinkel P et al (2020) Alport syndrome classification and management. Kidney Med 2:639\u2013649","journal-title":"Kidney Med"},{"key":"7046_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.848389","volume":"9","author":"E Chavez","year":"2022","unstructured":"Chavez E, Rodriguez J, Drexler Y, Fornoni A (2022) Novel therapies for Alport syndrome. Front Med 9:848389","journal-title":"Front Med"},{"key":"7046_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065522","volume":"24","author":"J Reiterova","year":"2023","unstructured":"Reiterova J, Tesar V (2023) Current and future therapeutical options in Alport syndrome. Int J Mol Sci 24:5522","journal-title":"Int J Mol Sci"},{"key":"7046_CR13","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/ki.2011.407","volume":"81","author":"O Gross","year":"2012","unstructured":"Gross O, Licht C, Anders HJ, Hoppe B, Beck B, Tonshoff B et al (2012) Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 81:494\u2013501","journal-title":"Kidney Int"},{"key":"7046_CR14","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/ndt\/gfae265","volume":"40","author":"R Torra","year":"2025","unstructured":"Torra R, Lipska-Zietkiewicz B, Acke F, Antignac C, Becker JU, Cornec-Le Gall E et al (2025) Diagnosis, management and treatment of the Alport syndrome - 2024 guideline on behalf of ERKNet, ERA and ESPN. Nephrol Dial Transplant 40:1091\u20131106","journal-title":"Nephrol Dial Transplant"},{"key":"7046_CR15","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.kint.2020.01.030","volume":"97","author":"MN Rheault","year":"2020","unstructured":"Rheault MN, Smoyer WE (2020) Long-term ACE inhibition in Alport syndrome: are the benefits worth the risks? Kidney Int 97:1104\u20131106","journal-title":"Kidney Int"},{"key":"7046_CR16","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.kint.2019.12.015","volume":"97","author":"O Gross","year":"2020","unstructured":"Gross O, Tonshoff B, Weber LT, Pape L, Latta K, Fehrenbach H et al (2020) A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport\u2019s syndrome. Kidney Int 97:1275\u20131286","journal-title":"Kidney Int"},{"key":"7046_CR17","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00467-020-04819-6","volume":"36","author":"CE Kashtan","year":"2021","unstructured":"Kashtan CE, Gross O (2021) Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020. Pediatr Nephrol 36:711\u2013719","journal-title":"Pediatr Nephrol"},{"key":"7046_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","volume":"66","author":"V Vallon","year":"2015","unstructured":"Vallon V (2015) The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 66:255\u2013270","journal-title":"Annu Rev Med"},{"key":"7046_CR19","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.83353","volume":"12","author":"M Ge","year":"2023","unstructured":"Ge M, Molina J, Kim JJ, Mallela SK, Ahmad A, Varona Santos J et al (2023) Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome. Elife 12:e83353","journal-title":"Elife"},{"key":"7046_CR20","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1016\/j.ekir.2024.09.014","volume":"9","author":"J Boeckhaus","year":"2024","unstructured":"Boeckhaus J, Gale DP, Simon J, Ding J, Zhang Y, Bergmann C et al (2024) SGLT2-inhibition in patients with Alport syndrome. Kidney Int Rep 9:3490\u20133500","journal-title":"Kidney Int Rep"},{"key":"7046_CR21","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/ndt\/gfae180","volume":"40","author":"O Gross","year":"2025","unstructured":"Gross O, Boeckhaus J, Weber LT, Heerspink HJL, Simon JF, Ahmed R et al (2025) Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport. Nephrol Dial Transplant 40:679\u2013687","journal-title":"Nephrol Dial Transplant"},{"key":"7046_CR22","unstructured":"National Institutes of Health. ClinicalTrials.gov (2024) Phase 3 clinical trial with dapagliflozin in chronic kidney disease in adolescents and young adult patients (DOUBLE_PROTECT). https:\/\/clinicaltrials.gov\/study\/NCT05944016. Accessed 10 Sept 2025"},{"key":"7046_CR23","doi-asserted-by":"publisher","first-page":"9995","DOI":"10.3390\/ijms22189995","volume":"22","author":"W Baran","year":"2021","unstructured":"Baran W, Krzeminska J, Szlagor M, Wronka M, Mlynarska E, Franczyk B et al (2021) Mineralocorticoid receptor antagonists-use in chronic kidney disease. Int J Mol Sci 22:9995","journal-title":"Int J Mol Sci"},{"key":"7046_CR24","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P et al (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385:2252\u20132263","journal-title":"N Engl J Med"},{"key":"7046_CR25","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1681\/ASN.0000000000000186","volume":"34","author":"Z Zhu","year":"2023","unstructured":"Zhu Z, Rosenkranz KAT, Kusunoki Y, Li C, Klaus M, Gross O et al (2023) Finerenone added to RAS\/SGLT2 blockade for CKD in Alport syndrome. Results of a randomized controlled trial with Col4a3-\/- mice. J Am Soc Nephrol 34:1513\u20131520","journal-title":"J Am Soc Nephrol"},{"key":"7046_CR26","unstructured":"National Institutes of Health. ClinicalTrials.gov (2024)A study to learn more about how well the study treatment finerenone works, how safe it is, how it moves into, through, and out of the body, and the effects it has on the body when taken with an ACE inhibitor or angiotensin receptor blocker in children with chronic kidney disease and proteinuria (FIONA). https:\/\/clinicaltrials.gov\/study\/NCT05196035. Accessed 10 Sept 2025"},{"key":"7046_CR27","unstructured":"National Institutes of Health. ClinicalTrials.gov (2024) A study to learn more about how safe the study treatment finerenone is in long-term use when taken with an ACE inhibitor or angiotensin receptor blocker over 18 months of use in children and young adults from 1 to 18 years of age with chronic kidney disease and proteinuria (FIONA OLE). https:\/\/clinicaltrials.gov\/study\/NCT05457283. Accessed 10 Sept 2025"},{"key":"7046_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G et al (2024) Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 391:109\u2013121","journal-title":"N Engl J Med"},{"key":"7046_CR29","doi-asserted-by":"publisher","first-page":"C243","DOI":"10.1152\/ajpcell.00147.2023","volume":"325","author":"B Lee","year":"2023","unstructured":"Lee B, Holstein-Rathlou NH, Sosnovtseva O, Sorensen CM (2023) Renoprotective effects of GLP-1 receptor agonists and SGLT-2 inhibitors-is hemodynamics the key point? Am J Physiol Cell Physiol 325:C243\u2013C256","journal-title":"Am J Physiol Cell Physiol"},{"key":"7046_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s44162-024-00065-8","volume":"4","author":"J Boeckhaus","year":"2025","unstructured":"Boeckhaus J, Mabillard H, Sayer JA (2025) GLP-1 receptor agonists-another promising therapy for Alport syndrome? J Rare Dis 4:5","journal-title":"J Rare Dis"},{"key":"7046_CR31","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/j.2040-4603.2011.tb00344.x","volume":"1","author":"DE Kohan","year":"2011","unstructured":"Kohan DE, Inscho EW, Wesson D, Pollock DM (2011) Physiology of endothelin and the kidney. Compr Physiol 1:883\u2013919","journal-title":"Compr Physiol"},{"key":"7046_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ndt\/gfi265","volume":"21","author":"M Ruiz-Ortega","year":"2006","unstructured":"Ruiz-Ortega M, Ruperez M, Esteban V, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G et al (2006) Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant 21:16\u201320","journal-title":"Nephrol Dial Transplant"},{"key":"7046_CR33","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","volume":"401","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U et al (2023) Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet 401:1584\u20131594","journal-title":"Lancet"},{"key":"7046_CR34","unstructured":"National Institutes of Health. ClinicalTrials.gov (2024) Study of sparsentan treatment in pediatrics with proteinuric glomerular diseases (EPPIK). https:\/\/clinicaltrials.gov\/study\/NCT05003986. Accessed 10 Sept 2025"},{"key":"7046_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043427","volume":"24","author":"I Martinez-Diaz","year":"2023","unstructured":"Martinez-Diaz I, Martos N, Llorens-Cebria C, Alvarez FJ, Bedard PW, Vergara A et al (2023) Endothelin receptor antagonists in kidney disease. Int J Mol Sci 24:3427","journal-title":"Int J Mol Sci"},{"key":"7046_CR36","unstructured":"National Institutes of Health. ClinicalTrials.gov (2024) Atrasentan in patients with proteinuric glomerular diseases (AFFINITY). https:\/\/clinicaltrials.gov\/study\/NCT04573920. Accessed 10 Sept 2025"},{"key":"7046_CR37","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/11905","volume":"22","author":"A Brooks-Wilson","year":"1999","unstructured":"Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M et al (1999) Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 22:336\u2013345","journal-title":"Nat Genet"},{"key":"7046_CR38","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1172\/JCI85939","volume":"126","author":"CE Pedigo","year":"2016","unstructured":"Pedigo CE, Ducasa GM, Leclercq F, Sloan A, Mitrofanova A, Hashmi T et al (2016) Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury. J Clin Invest 126:3336\u20133350","journal-title":"J Clin Invest"},{"key":"7046_CR39","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1172\/JCI125316","volume":"129","author":"GM Ducasa","year":"2019","unstructured":"Ducasa GM, Mitrofanova A, Mallela SK, Liu X, Molina J, Sloan A et al (2019) ATP-binding cassette A1 deficiency causes cardiolipin-driven mitochondrial dysfunction in podocytes. J Clin Invest 129:3387\u20133400","journal-title":"J Clin Invest"},{"key":"7046_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24890-3","volume":"12","author":"MB Wright","year":"2021","unstructured":"Wright MB, Varona Santos J, Kemmer C, Maugeais C, Carralot JP, Roever S et al (2021) Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux preserving kidney function in two models of kidney disease. Nat Commun 12:4662","journal-title":"Nat Commun"},{"key":"7046_CR41","unstructured":"National Institutes of Health. ClinicalTrials.gov (2024) Study to evaluate R3R01 in patients with Alport syndrome and patients with focal segmental glomerulosclerosis. https:\/\/clinicaltrials.gov\/study\/NCT05267262?cond=Alport%20Nephropathy&sort=StudyFirstPostDate&intr=r3r01&rank=1. Accessed 10 Sept 2025"},{"key":"7046_CR42","doi-asserted-by":"publisher","first-page":"16026","DOI":"10.1074\/jbc.271.27.16026","volume":"271","author":"PG Yancey","year":"2026","unstructured":"Yancey PG, Rodrigueza WV, Kilsdonk EP, Stoudt GW, Johnson WJ, Phillips MC et al (2026) Cellular cholesterol efflux mediated by cyclodextrins. Demonstration of kinetic pools and mechanism of efflux. J Biol Chem 271:16026\u201316034","journal-title":"J Biol Chem"},{"key":"7046_CR43","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/hmg\/ddab194","volume":"30","author":"JL Rodriguez-Gil","year":"2021","unstructured":"Rodriguez-Gil JL, Baxter LL, Watkins-Chow DE, Johnson NL, Davidson CD, Carlson SR et al (2021) Transcriptome of HPbetaCD-treated Niemann-Pick disease type C1 cells highlights GPNMB as a biomarker for therapeutics. Hum Mol Genet 30:2456\u20132468","journal-title":"Hum Mol Genet"},{"key":"7046_CR44","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.kint.2018.06.031","volume":"94","author":"A Mitrofanova","year":"2018","unstructured":"Mitrofanova A, Molina J, Varona Santos J, Guzman J, Morales XA, Ducasa GM et al (2018) Hydroxypropyl-beta-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis. Kidney Int 94:1151\u20131159","journal-title":"Kidney Int"},{"key":"7046_CR45","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.2337\/db13-0399","volume":"62","author":"S Merscher-Gomez","year":"2013","unstructured":"Merscher-Gomez S, Guzman J, Pedigo CE, Lehto M, Aguillon-Prada R, Mendez A et al (2013) Cyclodextrin protects podocytes in diabetic kidney disease. Diabetes 62:3817\u20133827","journal-title":"Diabetes"},{"key":"7046_CR46","unstructured":"National Institutes of Health. ClinicalTrials.gov (2025) P2a open label study to evaluate 2-HP\u03b2CD in subjects with diabetic kidney disease. https:\/\/clinicaltrials.gov\/study\/NCT06489340?intr=var200&rank=1. Accessed 10 Sept 2025"},{"key":"7046_CR47","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","volume":"78","author":"V Ratziu","year":"2023","unstructured":"Ratziu V, Harrison SA, Loustaud-Ratti V, Bureau C, Lawitz E, Abdelmalek M et al (2023) Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. J Hepatol 78:479\u2013492","journal-title":"J Hepatol"},{"key":"7046_CR48","doi-asserted-by":"publisher","first-page":"F792","DOI":"10.1152\/ajprenal.00292.2023","volume":"325","author":"BA Jones","year":"2023","unstructured":"Jones BA, Myakala K, Guha M, Davidson S, Adapa S, Lopez Santiago I et al (2023) Farnesoid x receptor prevents neutrophil extracellular traps via reduced sphingosine-1-phosphate in chronic kidney disease. Am J Physiol Renal Physiol 325:F792\u2013F810","journal-title":"Am J Physiol Renal Physiol"},{"key":"7046_CR49","unstructured":"National Institutes of Health. ClinicalTrials.gov (2024) Vonafexor ALPort syndrome efficacy & safety TRIAl-1 (ALPESTRIA-1) (ALPESTRIA-1). https:\/\/clinicaltrials.gov\/study\/NCT06425055?utm_source=chatgpt.com. Accessed 10 Sept 2025"},{"key":"7046_CR50","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.kint.2025.04.024","volume":"108","author":"A Mitrofanova","year":"2025","unstructured":"Mitrofanova A, Fontanella AM, Molina J, Zhang G, Mallela SK, Severino LU et al (2025) The enzyme SMPDL3b in podocytes decouples proteinuria from chronic kidney disease progression in experimental Alport syndrome. Kidney Int 108:253\u2013270","journal-title":"Kidney Int"},{"key":"7046_CR51","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1126\/science.1093131","volume":"303","author":"SW Altmann","year":"2004","unstructured":"Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G et al (2004) Niemann-pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 303:1201\u20131204","journal-title":"Science"},{"key":"7046_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103162","volume":"63","author":"J-J Kim","year":"2021","unstructured":"Kim J-J, David JM, Wilbon SS, Santos JV, Patel DM, Ahmad A et al (2021) Discoidin domain receptor 1 activation links extracellular matrix to podocyte lipotoxicity in Alport syndrome. EBioMedicine 63:103162","journal-title":"EBioMedicine"},{"key":"7046_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252313134","volume":"25","author":"JJ Kim","year":"2024","unstructured":"Kim JJ, Yang EJ, Molina David J, Cho S, Ficarella M, Pape N et al (2024) Ezetimibe enhances lipid droplet and mitochondria contact formation, improving fatty acid transfer and reducing lipotoxicity in Alport syndrome podocytes. Int J Mol Sci 25:13134","journal-title":"Int J Mol Sci"},{"key":"7046_CR54","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1111\/dom.15146","volume":"25","author":"NS Heinrich","year":"2023","unstructured":"Heinrich NS, Pedersen RP, Vestergaard MB, Lindberg U, Andersen UB, Haddock B et al (2023) Evaluation of the effects of ezetimibe on albuminuria and kidney fat in individuals with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 25:2605\u20132615","journal-title":"Diabetes Obes Metab"},{"key":"7046_CR55","doi-asserted-by":"publisher","first-page":"F1276","DOI":"10.1152\/ajprenal.00396.2014","volume":"308","author":"Y Gorin","year":"2015","unstructured":"Gorin Y, Cavaglieri RC, Khazim K, Lee DY, Bruno F, Thakur S et al (2015) Targeting NADPH oxidase with a novel dual Nox1\/Nox4 inhibitor attenuates renal pathology in type 1 diabetes. Am J Physiol Renal Physiol 308:F1276\u2013F1287","journal-title":"Am J Physiol Renal Physiol"},{"issue":"11S","key":"7046_CR56","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1681\/ASN.20233411S1223a","volume":"34","author":"T Christophe","year":"2023","unstructured":"Christophe T, Fresquet M, Morais MR, Lawless C, Lennon R (2023) The NOX inhibitor setanaxib combined with ramipril reduces glomerular function decline and fibrosis in a mouse model of Alport syndrome: TH-PO481. J Am Soc Nephrol 34(11S):223","journal-title":"J Am Soc Nephrol"},{"key":"7046_CR57","unstructured":"National Institutes of Health. ClinicalTrials.gov (2025) A study to evaluate setanaxib in patients with Alport syndrome. https:\/\/clinicaltrials.gov\/study\/NCT06274489?utm_source=chatgpt.com. Accessed 10 Sept 2025"},{"key":"7046_CR58","first-page":"573","volume":"10","author":"X Fan","year":"2024","unstructured":"Fan X, Wu L, Wang F, Liu D, Cen X, Xia H (2024) Mitophagy regulates kidney diseases. Kidney Dis (Basel) 10:573\u2013587","journal-title":"Kidney Dis (Basel)"},{"key":"7046_CR59","doi-asserted-by":"crossref","unstructured":"Lu Y, Li Z, Zhang S, Zhang T, Liu Y, Zhang (2023) Cellular mitophagy: mechanism, roles in diseases and small molecule pharmacological regulation. Theranostics 13:736\u2013766","DOI":"10.7150\/thno.79876"},{"key":"7046_CR60","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41573-021-00242-0","volume":"20","author":"IS Daehn","year":"2021","unstructured":"Daehn IS, Duffield JS (2021) The glomerular filtration barrier: a structural target for novel kidney therapies. Nat Rev Drug Discov 20:770\u2013788","journal-title":"Nat Rev Drug Discov"},{"key":"7046_CR61","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.2215\/CJN.02400222","volume":"17","author":"BA Warady","year":"2022","unstructured":"Warady BA, Pergola PE, Agarwal R, Andreoli S, Appel GB, Bangalore S et al (2022) Effects of bardoxolone methyl in Alport syndrome. Clin J Am Soc Nephrol 17:1763\u20131774","journal-title":"Clin J Am Soc Nephrol"},{"key":"7046_CR62","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1159\/000513777","volume":"52","author":"GM Chertow","year":"2021","unstructured":"Chertow GM, Appel GB, Andreoli S, Bangalore S, Block GA, Chapman AB et al (2021) Study design and baseline characteristics of the CARDINAL trial: a phase 3 study of bardoxolone methyl in patients with Alport syndrome. Am J Nephrol 52:180\u2013189","journal-title":"Am J Nephrol"},{"key":"7046_CR63","unstructured":"National Institutes of Health. ClinicalTrials.gov (2022) CARDINAL: phase 3 study of bardoxolone methyl in patients with Alport syndrome. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03019185. Accessed 10 Sept 2025"},{"key":"7046_CR64","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.redox.2016.12.022","volume":"11","author":"L Xiao","year":"2017","unstructured":"Xiao L, Xu X, Zhang F, Wang M, Xu Y, Tang D et al (2017) The mitochondria-targeted antioxidant MitoQ ameliorated tubular injury mediated by mitophagy in diabetic kidney disease via Nrf2\/PINK1. Redox Biol 11:297\u2013311","journal-title":"Redox Biol"},{"key":"7046_CR65","unstructured":"Reata Pharmaceuticals (2023) Termination of bardoxolone methyl and chronic kidney disease research. https:\/\/pkdcure.org\/wp-content\/uploads\/PKD_Bardoxolone-Notification.pdf. Accessed 10 Sept 2025"},{"key":"7046_CR66","unstructured":"National Institutes of Health. ClinicalTrials.gov (2023) EAGLE: study of bardoxolone methyl in patients with ADPKD. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03749447. Accessed 10 Sept 2025"},{"key":"7046_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1590458","volume":"16","author":"Z Liu","year":"2025","unstructured":"Liu Z, Fang D, Chen K, Dong L, Huang H, Chen Z (2025) Novel mitophagy inducer TJ0113 alleviates pulmonary inflammation during acute lung injury. Front Pharmacol 16:1590458","journal-title":"Front Pharmacol"},{"key":"7046_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1667879","volume":"16","author":"Z Liu","year":"2025","unstructured":"Liu Z, Fang D, Chen K, Dong L, Huang H, Chen Z (2025) Correction: novel mitophagy inducer TJ0113 alleviates pulmonary inflammation during acute lung injury. Front Pharmacol 16:1667879","journal-title":"Front Pharmacol"},{"key":"7046_CR69","unstructured":"National Institutes of Health. ClinicalTrials.gov (2024) A study of ELX-02 in patients with Alport syndrome. https:\/\/clinicaltrials.gov\/study\/NCT05448755. Accessed 11 September 2025"},{"key":"7046_CR70","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2024h8aac54m","volume":"35","author":"D Gale","year":"2024","unstructured":"Gale D, Bockenhauer D, Chan M et al (2024) Small molecule premature termination codon readthrough therapy: a phase 2 pediatric and adult trial in nonsense mutation Alport syndrome. J Am Soc Nephrol 35:10S","journal-title":"J Am Soc Nephrol"},{"key":"7046_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076101","volume":"24","author":"RN Wagner","year":"2023","unstructured":"Wagner RN, Wiessner M, Friedrich A, Zandanell J, Breitenbach-Koller H, Bauer JW (2023) Emerging personalized opportunities for enhancing translational readthrough in rare genetic diseases and beyond. Int J Mol Sci 24:6101","journal-title":"Int J Mol Sci"},{"key":"7046_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16605-x","volume":"11","author":"T Yamamura","year":"2020","unstructured":"Yamamura T, Horinouchi T, Adachi T, Terakawa M, Takaoka Y, Omachi K et al (2020) Development of an exon skipping therapy for X-linked Alport syndrome with truncating variants in COL4A5. Nat Commun 11:2777","journal-title":"Nat Commun"},{"key":"7046_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-023-05203-4","volume":"6","author":"R Hirayama","year":"2023","unstructured":"Hirayama R, Toyohara K, Watanabe K, Otsuki T, Araoka T, Mae SI et al (2023) Ipsc-derived type IV collagen \u03b15-expressing kidney organoids model Alport syndrome. Commun Biol 6:854","journal-title":"Commun Biol"},{"key":"7046_CR74","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/sj.gt.3301342","volume":"8","author":"P Heikkil\u00e4","year":"2001","unstructured":"Heikkil\u00e4 P, Tibell A, Morita T, Chen Y, Wu G, Sado Y et al (2001) Adenovirus-mediated transfer of type IV collagen alpha5 chain cDNA into swine kidney in vivo: deposition of the protein into the glomerular basement membrane. Gene Ther 8:882\u2013890","journal-title":"Gene Ther"},{"key":"7046_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12061159","volume":"12","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Zheng Q, Xie J (2024) Exploration of gene therapy for Alport syndrome. Biomedicines 12:1159","journal-title":"Biomedicines"},{"key":"7046_CR76","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-075138","volume":"14","author":"L Huang","year":"2024","unstructured":"Huang L, Zou J, Zhang Y, Gu J, Wu J, Zhang C (2024) Human umbilical cord mesenchymal stem cell therapy for renal dysfunction in Alport syndrome: protocol for an open-label, single-arm trial in China. BMJ Open 14:e075138","journal-title":"BMJ Open"},{"key":"7046_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-020-02011-z","volume":"11","author":"Q Xie","year":"2020","unstructured":"Xie Q, Liu R, Jiang J, Peng J, Yang C, Zhang W et al (2020) What is the impact of human umbilical cord mesenchymal stem cell transplantation on clinical treatment? Stem Cell Res Ther 11:519","journal-title":"Stem Cell Res Ther"},{"key":"7046_CR78","doi-asserted-by":"publisher","first-page":"7321","DOI":"10.1073\/pnas.0601436103","volume":"103","author":"H Sugimoto","year":"2006","unstructured":"Sugimoto H, Mundel TM, Sund M, Xie L, Cosgrove D, Kalluri R (2006) Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc Natl Acad Sci U S A 103:7321\u20137326","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7046_CR79","unstructured":"National Institutes of Health. ClinicalTrials.gov (2024) Human umbilical cord mesenchymal stem cells for Alport syndrome (HUCMSC). https:\/\/clinicaltrials.gov\/study\/NCT06731192?cond=Alport%20Nephropathy&sort=StudyFirstPostDate&rank=1. Accessed 10 Sept 2025"}],"updated-by":[{"DOI":"10.1007\/s00467-025-07087-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000}}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-07046-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-07046-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-07046-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T15:04:55Z","timestamp":1769612695000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-07046-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,16]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7046"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-07046-z","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,16]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00467-025-07087-4","URL":"https:\/\/doi.org\/10.1007\/s00467-025-07087-4","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.F. is inventor of pending or issued patents (US10, 183, 038, US 10,052, 345) aimed at diagnosing or treating proteinuric kidney diseases. She stands to gain royalties from her future commercialization of these patents. A.F. is Vice-President of L&F Health LLC and is a consultant for ZyVersa Therapeutics, Inc. ZyVersa Therapeutics, Inc has licensed worldwide rights to develop and commercialize hydroxypropyl-beta-cyclodextrin from L&F Research for the treatment of kidney disease. A.F holds equities in River 3 Renal Corporation. C.L.R. and J.J.K. have no conflicts of interest to disclose. Although some experimental agents discussed (e.g., HP\u03b2CD, R3R01) are linked to these disclosures, the studies cited were performed independently, and their findings have not been influenced by these relationships.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}